Pharmaids [PHARMAID] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Pharmaids Pharmaceuticals Limited wins in 4 metrics, Sun Pharmaceutical Industries Ltd. wins in 14 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pharmaids Pharmaceuticals Limited | Sun Pharmaceutical Industries Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 2,023.33 | 36.73 | Sun Pharmaceutical Industries Ltd. |
| Price-to-Book Ratio | 2.11 | 5.15 | Pharmaids Pharmaceuticals Limited |
| Debt-to-Equity Ratio | 39.24 | 6.68 | Sun Pharmaceutical Industries Ltd. |
| PEG Ratio | 74.19 | 3.59 | Sun Pharmaceutical Industries Ltd. |
| EV/EBITDA | -7.84 | 23.61 | Sun Pharmaceutical Industries Ltd. |
| Profit Margin (TTM) | -54.23% | 19.21% | Sun Pharmaceutical Industries Ltd. |
| Operating Margin (TTM) | -54.88% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| EBITDA Margin (TTM) | N/A | 26.17% | N/A |
| Return on Equity | -19.58% | 15.08% | Sun Pharmaceutical Industries Ltd. |
| Return on Assets (TTM) | -8.99% | 11.87% | Sun Pharmaceutical Industries Ltd. |
| Free Cash Flow (TTM) | $-264.72M | $119.44B | Sun Pharmaceutical Industries Ltd. |
| Dividend Yield | N/A | 0.97% | N/A |
| 1-Year Return | -50.97% | 7.25% | Sun Pharmaceutical Industries Ltd. |
| Price-to-Sales Ratio (TTM) | 4.28 | 7.05 | Pharmaids Pharmaceuticals Limited |
| Enterprise Value | $1.29B | $3,783.37B | Sun Pharmaceutical Industries Ltd. |
| EV/Revenue Ratio | 5.05 | 6.66 | Pharmaids Pharmaceuticals Limited |
| Gross Profit Margin (TTM) | 56.76% | 80.96% | Sun Pharmaceutical Industries Ltd. |
| Revenue per Share (TTM) | $7 | $237 | Sun Pharmaceutical Industries Ltd. |
| Earnings per Share (Diluted) | $-5.13 | $45.46 | Sun Pharmaceutical Industries Ltd. |
| Beta (Stock Volatility) | 0.06 | 0.11 | Pharmaids Pharmaceuticals Limited |
Pharmaids Pharmaceuticals Limited vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pharmaids Pharmaceuticals Limited | -1.88% | -2.05% | -8.42% | -22.03% | -45.59% | -43.03% |
| Sun Pharmaceutical Industries Ltd. | -0.08% | -3.03% | -1.92% | 2.17% | -1.01% | 3.92% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pharmaids Pharmaceuticals Limited | -50.97% | 1.30% | 33.07% | 991.37% | 692.17% | 205.54% |
| Sun Pharmaceutical Industries Ltd. | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
Performance & Financial Health Analysis: Pharmaids Pharmaceuticals Limited vs Sun Pharmaceutical Industries Ltd.
| Metric | PHARMAID | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.09B | ₹3.88T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 7,801 | 3,903,142 |
| 90 Day Avg. Volume | 13,247 | 3,253,866 |
| Last Close | ₹27.18 | ₹1,788.50 |
| 52 Week Range | ₹25.60 - ₹70.00 | ₹1,548.00 - ₹1,916.60 |
| % from 52W High | -61.17% | -6.68% |
| All-Time High | ₹87.46 (Nov 11, 2024) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -68.92% | -8.77% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | 0.14% |
| Quarterly Earnings Growth | 0.15% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | -0.54% | 0.19% |
| Operating Margin (TTM) | -0.55% | 0.26% |
| Return on Equity (TTM) | -0.20% | 0.15% |
| Debt to Equity (MRQ) | 39.24 | 6.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹14.65 | ₹324.46 |
| Cash per Share (MRQ) | ₹0.07 | ₹115.87 |
| Operating Cash Flow (TTM) | ₹-278,094,000 | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹-107,766,000 | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.97% |
| Last 12-Month Dividend | N/A | ₹16.50 |
Valuation & Enterprise Metrics Analysis: Pharmaids Pharmaceuticals Limited vs Sun Pharmaceutical Industries Ltd.
| Metric | PHARMAID (Apr 24, 2026) | SUNPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 2,023.33 | 36.73 |
| Forward P/E | N/A | 29.48 |
| PEG Ratio | 74.19 | 3.59 |
| Price to Sales (TTM) | 4.28 | 7.05 |
| Price to Book (MRQ) | 2.11 | 5.15 |
| Market Capitalization | ||
| Market Capitalization | ₹1.09B | ₹3.88T |
| Enterprise Value | ₹1.29B | ₹3.78T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.05 | 6.66 |
| Enterprise to EBITDA | -7.84 | 23.61 |
| Risk & Other Metrics | ||
| Beta | 0.06 | 0.11 |
| Book Value per Share (MRQ) | ₹14.65 | ₹324.46 |
Financial Statements Comparison: Pharmaids Pharmaceuticals Limited vs Sun Pharmaceutical Industries Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | PHARMAID (2025) | SUNPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 188.13M | 520.41B |
| Cost of Goods Sold | 142.75M | 121.98B |
| COGS % of Revenue | 75.9% | 23.4% |
| Gross Profit | 45.38M | 398.44B |
| Gross Margin | 24.1% | 76.6% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | -151.64M | 125.81B |
| Operating Margin | -80.6% | 24.2% |
| EBITDA | -127.33M | 167.25B |
| EBITDA Margin | -67.7% | 32.1% |
| Pre-Tax Income | -172.79M | 137.52B |
| Pre-Tax Income % of Revenue | -91.8% | 26.4% |
| Income Tax | -37.74M | 27.72B |
| Income Tax % of Revenue | -20.1% | 5.3% |
| Net Income (Profit) | -135.05M | 109.65B |
| Profit Margin | -71.8% | 21.1% |
Balance Sheet & Liquidity Metrics
| Metric | PHARMAID (2025) | SUNPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 21.45M | 102.69B |
| Total Current Assets | 223.07M | 526.24B |
| Total Current Assets % of Revenue | 118.6% | 101.1% |
| Total Current Liabilities | 287.15M | 181.94B |
| Total Current Liabilities % of Revenue | 152.6% | 35.0% |
| Long-Term Debt | 331.19M | 3.58B |
| Long-Term Debt % of Revenue | 176.0% | 0.7% |
| Total Shareholders Equity | 550.42M | 724.86B |
| Retained Earnings | -266.77M | 578.62B |
| Retained Earnings % of Revenue | -141.8% | 111.2% |
| Property, Plant & Equipment | 19.32M | 100.36B |
Cash Flow Statement Comparison
| Metric | PHARMAID (2025) | SUNPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | -278.09M | 110.84B |
| Operating Cash Flow % of Revenue | -147.8% | 21.3% |
| Capital Expenditures | -122.62M | -20.68B |
| Free Cash Flow | -264.72M | 119.44B |
| FCF Margin | -140.7% | 23.0% |
| Debt Repayment | -49.10M | -43.44B |
| Common Stock Repurchase | N/A | -29.00B |
Short Interest & Institutional Ownership Analysis
| Metric | PHARMAID | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 35.27M | 2.40B |
| Float Shares | 6.95M | 1.07B |
| % Held by Insiders | 83.97% | 55.62% |
| % Held by Institutions | 0.00% | 28.69% |
| % Held by Public | 16.03% | 15.69% |
Dividend Analysis & Yield Comparison: Pharmaids Pharmaceuticals Limited vs Sun Pharmaceutical Industries Ltd.
| Metric | PHARMAID | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹16.50 |
| Last 12-Month Dividend Yield | N/A | 0.97% |
| 3-Year Avg Annual Dividend | N/A | ₹17.33 |
| 3-Year Avg Dividend Yield | N/A | 0.51% |
| 3-Year Total Dividends | N/A | ₹52.00 |
| Ex-Dividend Date | N/A | Feb 05, 2026 |